Ixekizumab Phase 3 Trial for Psoriasis and Obesity Completes Primary Phase

The Phase 3 clinical trial (NCT06588283) investigating ixekizumab concomitantly administered with tirzepatide for adults with moderate-to-severe plaque psoriasis and obesity or overweight completed its primary phase on 2026-01-08. This marks a significant milestone for the study, which aims to evaluate the combined therapeutic effects of these two agents.

Background

The study, titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight," explores a novel combination approach. Ixekizumab is an existing treatment for psoriasis, and this trial investigates its potential synergistic benefits when combined with tirzepatide in patients who also present with obesity or overweight. The main purpose of this study is to demonstrate that participants receiving ixekizumab and tirzepatide concomitantly will show improvement in their psoriasis and achieve weight reduction compared to those receiving ixekizumab alone.

Trial design

The study (NCT06588283) is a Phase 3 trial that enrolled 250 participants. It focuses on adults diagnosed with Psoriasis and Obesity or overweight, specifically those with moderate-to-severe plaque psoriasis and at least one weight-related comorbid condition. The interventions being studied are ixekizumab and tirzepatide. Participation in the study includes up to 12 visits and could last up to 61 weeks, encompassing screening, an open-label treatment period, and a post-treatment follow-up period. The trial is currently listed as ACTIVE_NOT_RECRUITING.

What this means

The primary completion of this Phase 3 trial indicates that the main data collection period for the study's primary objectives has concluded. While specific outcome measurements are not yet available, the completion of this phase is a crucial step towards understanding the efficacy and safety profile of ixekizumab in combination with tirzepatide for this specific patient population. The study's focus on both psoriasis improvement and weight reduction addresses significant comorbidities, potentially offering a comprehensive treatment strategy for patients with moderate-to-severe plaque psoriasis who are also obese or overweight. Clinicians and patients will await the full results to assess the potential benefits of this combination therapy.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06588283, titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight," was posted on 2026-01-08 on clinicaltrials.gov.